Depemokimab, an ultra-long-acting biologic agent with enhanced binding affinity for interleukin-5, may improve outcomes in patients with asthma with an eosinophilic phenotype. New research ...

Prevention of drug-resistant tuberculosis is a global health priority. However, trials evaluating the effectiveness of treating Mycobacterium tuberculosis infection among contacts of persons with ...

From August 8, 2018, to January 14, 2020, we vaccinated 265,183 participants. Of these vaccinees, 102,515 were monitored on days 0, 3, and 21 for safety. Among the contacts and contacts-of ...

Worldwide, approximately 2 million children younger than 15 years of age are infected with multidrug-resistant (MDR) Mycobacterium tuberculosis, with MDR tuberculosis developing in approximately ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Dr. James Q. Zhou (Medicine): A 56-year-old woman with metabolic dysfunction–associated steatohepatitis and cirrhosis was admitted to this hospital because of end-stage liver disease. The ...

This case vignette about a boy with cough, congestion, and fever is accompanied by two essays, one supporting empirical treatment with antibiotics for presumed bacterial pneumonia and the other ...

The author describes the science behind a study of ponsegromab to treat cancer cachexia. Ponsegromab suppresses a pathway in neurons located in specific regions of the brain stem.

Trials evaluating the effectiveness of treating Mycobacterium tuberculosis infection among contacts of persons with drug-resistant tuberculosis are lacking. New research findings are summarized in ...

Hippocrates, the father of medicine (460 to 370 b.c.), described cachexia as a condition in which “the flesh is consumed and becomes water,…the abdomen fills with water, the feet and legs ...